紫杉醇药物涂层球囊前使用切割球囊与普通球囊行血管准备:DASBAD随机对照试验
DASBAD 研究为单中心、单盲、平行组、优效性随机对照试验,纳入股腘动脉病变合并慢性肢体威胁性缺血患者 83 例,比较 AngioSculpt 切割球囊与普通球囊在 Luminor 药物涂层球囊前的血管准备效果。
要点
- 切割球囊血管准备较普通球囊显著降低补救性支架置入率(5% vs 33%)。
- 切割球囊组一期通畅率更高(91% vs 70%),手术费用更低。
- 适用人群为股腘动脉病变合并 Rutherford 4 或 5 级慢性肢体威胁性缺血患者。
核心结论
- 在慢性肢体威胁性缺血的股腘动脉病变中,药物涂层球囊前使用切割球囊行血管准备较普通球囊显著减少补救性支架置入,并与更高一期通畅率和更低手术费用相关。
研究设计与样本
- 单中心、单盲、平行组、优效性随机对照试验,纳入慢性肢体威胁性缺血合并股腘动脉病变且 Rutherford 分级为 4 或 5 级的患者,随机分为普通球囊组(对照)与切割球囊组行血管准备,每组计划样本量 39 例。
主要发现
- 切割球囊组与普通球囊组平均病变长度分别为 235 ± 134 mm 和 219 ± 130 mm。
- 补救性支架置入率普通球囊组为 33%,切割球囊组为 5%(p = .003)。
- 总体一期通畅率切割球囊组为 91%,普通球囊组为 70%(p = .035)。
- 切割球囊组每例患者手术费用较普通球囊组低 108 欧元(p = .003)。
关键数值与推荐
- 主要终点补救性支架置入定义为索引手术中因残余狭窄 > 30% 或 Kobayashi 分型 C 型夹层而置入支架。
- 一期通畅定义为双功超声收缩期峰值流速比 < 2.5 且无临床驱动的靶病变血运重建。
- 手术费用定义为索引手术中所用全部球囊和支架的总费用。
临床怎么用
- 对于慢性肢体威胁性缺血合并股腘动脉病变患者,在药物涂层球囊治疗前可考虑使用切割球囊行血管准备,以降低补救性支架置入需求并改善一期通畅率。
局限性
- 本研究为单中心、单盲设计,样本量较小(共 83 例),平均随访 517 ± 272 天,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Plain balloon angioplasty (PBA) remains the standard technique for vessel preparation in peripheral artery disease. This prospective, single centre, single blind, parallel group, superiority randomised trial enrolled chronic limb threatening ischaemia (CLTI) patients with femoropopliteal (FP) lesions. It evaluated whether AngioSculpt scoring balloon (SB) use, compared with PBA, before Luminor drug coated balloon (DCB) angioplasty in FP lesions and CLTI reduces the need for bailout stenting and improves patency without increasing procedure costs. METHODS: Patients with FP disease and Rutherford category four or five were randomised to PBA (control) or SB as vessel preparation. The sample size was calculated based on expected bailout stenting rates from previous studies, requiring 39 patients per arm. The primary endpoint was bailout stenting, defined as stent implantation during the index procedure for > 30% residual stenosis or type C dissection (Kobayashi classification). Secondary endpoints included primary patency, defined as duplex ultrasound peak systolic velocity ratio < 2.5 without clinically driven target lesion revascularisation, and procedure cost, defined as the total cost of all balloons and stents used during the index procedure. RESULTS: Eighty-three subjects were enrolled between September 2020 and November 2022 (43 SB, 40 PBA). Mean follow up was 517 ± 272 days. Mean lesion length was 235 ± 134 mm in the SB group and 219 ± 130 mm in the control group. Bailout stenting was required in 33% of PBA vs. 5% of SB (p = .003). Overall primary patency was higher in the SB group (91% vs. 70%; p = .035). Procedure costs were €108 lower per patient in the SB cohort (p = .003). CONCLUSIONS: In this study, the use of an SB for vessel preparation before DCB angioplasty in CLTI patients with FP lesions significantly reduced the need for bailout stenting and was associated with improved primary patency and lower procedure costs compared with PBA. (ClinicalTrials registration ID: NCT07136883).
引用
- Sirvent M, Riera C, Gil M, et al. Drug Coated Balloon Angioplasty after Plain or Scoring Balloon for Vessel Preparation for Femoropopliteal Arterial Disease (DASBAD): A Randomised Controlled Trial. Eur J Vasc Endovasc Surg. 2026. PMID: 42242352. doi:10.1016/j.ejvs.2026.05.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。